Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Nat Immunol ; 24(6): 941-954, 2023 06.
Article in English | MEDLINE | ID: mdl-37095378

ABSTRACT

The range of vaccines developed against severe acute respiratory syndrome coronavirus 2 (SARS­CoV­2) provides a unique opportunity to study immunization across different platforms. In a single-center cohort, we analyzed the humoral and cellular immune compartments following five coronavirus disease 2019 (COVID-19) vaccines spanning three technologies (adenoviral, mRNA and inactivated virus) administered in 16 combinations. For adenoviral and inactivated-virus vaccines, heterologous combinations were generally more immunogenic compared to homologous regimens. The mRNA vaccine as the second dose resulted in the strongest antibody response and induced the highest frequency of spike-binding memory B cells irrespective of the priming vaccine. Priming with the inactivated-virus vaccine increased the SARS-CoV-2-specific T cell response, whereas boosting did not. Distinct immune signatures were elicited by the different vaccine combinations, demonstrating that the immune response is shaped by the type of vaccines applied and the order in which they are delivered. These data provide a framework for improving future vaccine strategies against pathogens and cancer.


Subject(s)
COVID-19 Vaccines , COVID-19 , Humans , Antibodies, Viral , COVID-19/prevention & control , SARS-CoV-2 , T-Lymphocytes , Immunogenicity, Vaccine
2.
BMC Health Serv Res ; 22(1): 948, 2022 Jul 26.
Article in English | MEDLINE | ID: mdl-35883128

ABSTRACT

OBJECTIVE: Analyze the cost contributors and their impact on the drug cost avoidance (DCA) resulting from cancer clinical trials over the period of 2015-2020 in a tertiary-level hospital in Spain (HCUVA). METHODS: We performed a cross-sectional, observational, retrospective study of a total of 53 clinical trials with 363 patients enrolled. We calculated the DCA from the price of the best standard of care (i.e.: drugs that the institution would otherwise fund). A linear regression model was used to determine cost contributors and estimate their impact. RESULTS: The total DCA was ~ 4.9 million euros (31 clinical trials; 177 enrollees), representing ~ 30% and ~ 0,05% approximately of the annual pharmaceutical expenditures at the HCUVA and for the Spanish Health System, respectively. Cancer type analysis showed that lung cancer had the highest average DCA by trial, indicating that treatments in these trials were the most expensive. Linear regression analysis showed that the number of patients in a trial did not significantly affect that trial's DCA. Instead, cancer type, phase trials, and intention of treatment were significant cost contributors to DCA. Compared to digestive cancer trials, breast and lung trials were significantly more expensive, (p < 0.05 and p < 0.1, respectively). Phase III trials were more expensive than Phase II (p < 0.01) and adjuvant trials were less expensive than palliative (p < 0.05). CONCLUSION: We studied cost contributors that significantly impacted the estimated DCA from cancer clinical trials. Our work provides the groundwork to explore DCA contributors with potential to enhance public relations material and serve as a negotiating tool for budgeting, thus playing an important role to inform decisions about resource allocation.


Subject(s)
Drug Costs , Lung Neoplasms , Cross-Sectional Studies , Humans , Retrospective Studies , Spain
3.
Cad Saude Publica ; 38(4): ES219821, 2022.
Article in Spanish | MEDLINE | ID: mdl-35544877

ABSTRACT

Seroepidemiological studies help identify the indirect distribution of diseases, detecting serological markers of immunity and demonstrating undiagnosed infections in the general population. The objectives were to estimate the seroprevalence of SARS-CoV-2 antibodies in Córdoba, Argentina, from December 2020 to January 2021 and to identify factors associated with the virus' contagiousness. A population-based cross-sectional observational study was performed in 3,225 individuals over two years of age living in Córdoba city, selected by multiple-stage random sampling proportional to distribution by gender, age group, and socioeconomic status in the city's population. Clinical characteristics, anthropometry, and comorbidities were collected by interview. Qualitative serological testing was performed for detection of SARS-CoV-2 nucleocapsid IgG antibodies (ARCHITECT, Abbott). SARS-CoV-2 seroprevalence was estimated for the total population and by age group, sex, socioeconomic status, and presence of target diseases. Prevalence ratios (PR) were estimated using a log-binomial regression model. SARS-CoV-2 seropositivity was 16.68% (95%CI: 15.41-18.01). Age 2 to 18 years, living in neighborhoods with low socioeconomic status, and obesity increased the odds of seropositivity (PR = 1.50; 95%CI: 1.10-2.04, PR = 1.91; 95%CI: 1.34-2.67 and PR = 1.39; 95%CI: 1.04-1.85). The results indicate that the city of Córdoba displays differential attributes that increase the likelihood of a positive SARS-CoV-2 antibody test. This allows targeting epidemiological surveillance strategies to reduce the spread of the virus.


Los estudios seroepidemiológicos permiten conocer la distribución indirecta de las enfermedades, detectando marcadores séricos de inmunidad y demostrando infecciones no diagnosticadas en la población general. El objetivo fue estimar la seroprevalencia de anticuerpos contra el SARS-CoV-2, en Córdoba, Argentina, entre diciembre de 2020 y enero de 2021, e identificar factores asociados a la contagiosidad del virus. Se realizó un estudio observacional transversal, de base poblacional, con 3.225 individuos mayores de 2 años, residentes en Córdoba Capital, que fueron seleccionados mediante un diseño de muestreo aleatorio en múltiples etapas, proporcional a la distribución por género, franja etaria y nivel socioeconómico de la población de Córdoba. Las características clínicas, antropometría y comorbilidades se recogieron mediante entrevistas. Se realizó un test serológico cualitativo para la detección de anticuerpos IgG antinucleocápside para SARS-CoV-2 (ARCHITECT, Abbott). La seroprevalencia del SARS-CoV-2 se estimó en la población y por franja de edad, sexo, nivel socioeconómico y presencia de las patologías estudiadas. Las razones de prevalencia (RP) se estimaron usando un modelo de regresión log-binomial. La seropositividad para SARS-CoV-2 fue de 16,68% (IC95%: 15,41-18,01). Tener entre 2 y 18 años, residir en barrios con nivel socioeconómico bajo y la presencia de obesidad, aumentaron la oportunidad de seropositividad (RP = 1,50; IC95%: 1,10-2,04, RP = 1,91; IC95%: 1,34-2,67 y RP = 1,39; IC95%: 1,04-1,85). Los resultados indican que en Córdoba Capital existen atributos diferenciales que aumentan la posibilidad de ser seropositivo para SARS-CoV-2. Esto permite dirigir estrategias de vigilancia epidemiológica para reducir la propagación del virus.


Os estudos soroepidemiológicos permitem conhecer a distribuição indireta das doenças, detectando marcadores séricos de imunidade e demonstrando infecções não diagnosticadas na população geral. O objetivo foi estimar a soroprevalência de anticorpos contra o SARS-CoV-2, em Córdoba, Argentina, entre dezembro de 2020 e janeiro de 2021, e identificar fatores associados à contagiosidade do vírus. Um estudo observacional transversal foi realizado, de base populacional, com 3.225 indivíduos maiores de 2 anos, residentes em Córdoba Capital, que foram selecionados por meio de um delineamento de amostragem aleatória em múltiplos estágios, proporcional à distribuição de gênero, a faixa etária e o nível socioeconômico da população de Córdoba. As características clínicas, antropometria e comorbidades foram coletadas por meio de entrevistas. Um teste sorológico qualitativo foi realizado para a detecção de anticorpos IgG anti-nucleocapsídeo para SARS-CoV-2 (ARCHITECT, Abbott). A soroprevalência do SARS-CoV-2 foi estimada na população e por faixa etária, sexo, nível socioeconômico e presença das patologias estudadas. Razões de prevalência (RP) foram estimadas usando um modelo de regressão log-binomial. A soropositividade para SARS-CoV-2 foi de 16,68% (IC95%: 15,41-18,01). Ter entre 2 e 18 años, residir em bairros com nível socioeconômico baixo e a presença de obesidade aumentaram a chance de soropositividade (RP = 1,50; IC95%: 1,10-2,04, RP = 1,91; IC95%: 1,34-2,67 e RP = 1,39; IC95%: 1,04-1,85). Os resultados indicam que em Córdoba Capital existem atributos diferenciais que aumentam a possibilidade de ser soropositivo para SARS-CoV-2. Isso permite direcionar estratégias de vigilância epidemiológica para reduzir a propagação do vírus.


Subject(s)
COVID-19 , Adolescent , Antibodies, Viral , Argentina/epidemiology , Brazil , COVID-19/epidemiology , Child , Child, Preschool , Cross-Sectional Studies , Humans , Immunoglobulin G , SARS-CoV-2 , Seroepidemiologic Studies
4.
Rev Panam Salud Publica ; 46: e39, 2022.
Article in Spanish | MEDLINE | ID: mdl-35509644

ABSTRACT

Objective: To determine the effectiveness of vaccination against SARS-CoV-2 in preventing illness and death from COVID-19 in Córdoba, Argentina, during the period from January through June 2021. Methods: A retrospective cohort study was conducted among 1,139,458 residents of the province of Córdoba. Multiple logistic regression models were developed to describe the relationship between vaccination and the presence of SARS-CoV-2 or death from COVID-19, while taking account of comorbidities and chronic disease risk factors and adjusting for sex and age. Results: Among the general population, having received one or two doses of vaccine reduced the risk of illness by 98.8% and 99.3%, respectively, and the risk of dying by 83% and 96.5%, respectively. Among those who developed COVID-19, the probability of dying was reduced by 57% and 80%, respectively. Regarding probability of death, risk increased with age, with being male, and with obesity, arterial hypertension, and diabetes mellitus. Conclusion: Vaccination is effective and protects against the risk of getting COVID-19, developing severe disease, or dying. Having obesity, arterial hypertension, or diabetes mellitus, in descending order, increases the risk of death.


Objetivo: Conhecer a eficácia da vacinação contra SARS-CoV-2 para prevenir o desenvolvimento de doença e morte por COVID-19 em Córdoba, Argentina, no período de janeiro a junho de 2021. Métodos: Foi realizado um estudo de coorte retrospectivo em 1.139.458 residentes da província de Córdoba. Foram construídos modelos de regressão logística múltipla que relacionaram a vacinação à presença de SARS-CoV-2 ou morte por COVID-19, considerando comorbidades e fatores de risco para doenças crônicas e ajustando por sexo e idade. Resultados: Ter recebido uma ou duas doses da vacina na população geral reduziu o risco de adoecimento em 98,8% e 99,3%, respectivamente; e de morrer, em 83% e 96,5%, respectivamente. Naqueles que contraíram COVID-19, a probabilidade de morrer foi reduzida em 57% e 80%, respectivamente. Em relação à probabilidade de morte, o risco aumentou com o aumento da idade e para o sexo masculino, ou com a presença de obesidade, hipertensão arterial ou diabetes mellitus. Conclusão: A vacinação é efetiva e protege contra a possibilidade de contrair COVID-19, desenvolver doença grave ou morrer. A presença de obesidade, hipertensão arterial ou diabetes mellitus, em ordem decrescente, aumenta o risco de morte.

5.
Article in Spanish | PAHO-IRIS | ID: phr-55931

ABSTRACT

[RESUMEN]. Objetivo. Conocer la efectividad de la vacunación contra SARS-CoV-2 para prevenir el desarrollo de enfermedad y muerte por COVID-19 en Córdoba, Argentina, en el periodo enero-junio de 2021. Métodos. Se llevó a cabo un estudio de cohorte retrospectivo en 1 139 458 residentes en la provincia de Córdoba. Se construyeron modelos de regresión logística múltiple que relacionaron la vacunación con la infección por SARS-CoV-2 o la muerte por COVID-19, considerando comorbilidades y factores de riesgo de enfermedades crónicas y ajustando por sexo y edad. Resultados. El haber recibido una o dos dosis de vacuna en la población general redujo el riesgo de enfermar un 98,8% y 99,3%, respectivamente; y de morir un 83% y 96,5%, respectivamente. En quienes contrajeron COVID-19, la probabilidad de morir se redujo en 57% y 80%, respectivamente. En cuanto a la probabilidad de muerte, el riesgo aumentó a medida que aumentaba la edad y con la pertenencia al sexo masculino o la presencia de obesidad, hipertensión arterial o diabetes mellitus. Conclusión. La vacunación es efectiva y protege contra la posibilidad de contraer COVID-19, desarrollar enfermedad grave o morir. Presentar obesidad, hipertensión arterial o diabetes mellitus, en orden decreciente, aumentan el riesgo de morir.


[ABSTRACT]. Objective. To determine the effectiveness of vaccination against SARS-CoV-2 in preventing illness and death from COVID-19 in Córdoba, Argentina, during the period from January through June 2021. Methods. A retrospective cohort study was conducted among 1,139,458 residents of the province of Córdoba. Multiple logistic regression models were developed to describe the relationship between vaccination and the presence of SARS-CoV-2 or death from COVID-19, while taking account of comorbidities and chronic disease risk factors and adjusting for sex and age. Results. Among the general population, having received one or two doses of vaccine reduced the risk of illness by 98.8% and 99.3%, respectively, and the risk of dying by 83% and 96.5%, respectively. Among those who developed COVID-19, the probability of dying was reduced by 57% and 80%, respectively. Regarding probability of death, risk increased with age, with being male, and with obesity, arterial hypertension, and diabetes mellitus. Conclusion. Vaccination is effective and protects against the risk of getting COVID-19, developing severe disease, or dying. Having obesity, arterial hypertension, or diabetes mellitus, in descending order, increases the risk of death.


[RESUMO]. Objetivo. Conhecer a eficácia da vacinação contra SARS-CoV-2 para prevenir o desenvolvimento de doença e morte por COVID-19 em Córdoba, Argentina, no período de janeiro a junho de 2021. Métodos. Foi realizado um estudo de coorte retrospectivo em 1.139.458 residentes da província de Córdoba. Foram construídos modelos de regressão logística múltipla que relacionaram a vacinação à presença de SARS-CoV-2 ou morte por COVID-19, considerando comorbidades e fatores de risco para doenças crônicas e ajustando por sexo e idade. Resultados. Ter recebido uma ou duas doses da vacina na população geral reduziu o risco de adoecimento em 98,8% e 99,3%, respectivamente; e de morrer, em 83% e 96,5%, respectivamente. Naqueles que contraíram COVID-19, a probabilidade de morrer foi reduzida em 57% e 80%, respectivamente. Em relação à probabilidade de morte, o risco aumentou com o aumento da idade e para o sexo masculino, ou com a presença de obesidade, hipertensão arterial ou diabetes mellitus. Conclusão. A vacinação é efetiva e protege contra a possibilidade de contrair COVID-19, desenvolver doença grave ou morrer. A presença de obesidade, hipertensão arterial ou diabetes mellitus, em ordem decrescente, aumenta o risco de morte.


Subject(s)
Immunization , Repeated Dose , COVID-19 , COVID-19 Vaccines , Effectiveness , Argentina , Immunization , Repeated Dose , COVID-19 Vaccines , Effectiveness , Immunization , Repeated Dose , COVID-19 Vaccines , Effectiveness
6.
Rev. panam. salud pública ; 46: e39, 2022. tab, graf
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1432042

ABSTRACT

RESUMEN Objetivo. Conocer la efectividad de la vacunación contra SARS-CoV-2 para prevenir el desarrollo de enfermedad y muerte por COVID-19 en Córdoba, Argentina, en el periodo enero-junio de 2021. Métodos. Se llevó a cabo un estudio de cohorte retrospectivo en 1 139 458 residentes en la provincia de Córdoba. Se construyeron modelos de regresión logística múltiple que relacionaron la vacunación con la infección por SARS-CoV-2 o la muerte por COVID-19, considerando comorbilidades y factores de riesgo de enfermedades crónicas y ajustando por sexo y edad. Resultados. El haber recibido una o dos dosis de vacuna en la población general redujo el riesgo de enfermar un 98,8% y 99,3%, respectivamente; y de morir un 83% y 96,5%, respectivamente. En quienes contrajeron COVID-19, la probabilidad de morir se redujo en 57% y 80%, respectivamente. En cuanto a la probabilidad de muerte, el riesgo aumentó a medida que aumentaba la edad y con la pertenencia al sexo masculino o la presencia de obesidad, hipertensión arterial o diabetes mellitus. Conclusión. La vacunación es efectiva y protege contra la posibilidad de contraer COVID-19, desarrollar enfermedad grave o morir. Presentar obesidad, hipertensión arterial o diabetes mellitus, en orden decreciente, aumentan el riesgo de morir.


ABSTRACT Objective. To determine the effectiveness of vaccination against SARS-CoV-2 in preventing illness and death from COVID-19 in Córdoba, Argentina, during the period from January through June 2021. Methods. A retrospective cohort study was conducted among 1,139,458 residents of the province of Córdoba. Multiple logistic regression models were developed to describe the relationship between vaccination and the presence of SARS-CoV-2 or death from COVID-19, while taking account of comorbidities and chronic disease risk factors and adjusting for sex and age. Results. Among the general population, having received one or two doses of vaccine reduced the risk of illness by 98.8% and 99.3%, respectively, and the risk of dying by 83% and 96.5%, respectively. Among those who developed COVID-19, the probability of dying was reduced by 57% and 80%, respectively. Regarding probability of death, risk increased with age, with being male, and with obesity, arterial hypertension, and diabetes mellitus. Conclusion. Vaccination is effective and protects against the risk of getting COVID-19, developing severe disease, or dying. Having obesity, arterial hypertension, or diabetes mellitus, in descending order, increases the risk of death.


RESUMO Objetivo. Conhecer a eficácia da vacinação contra SARS-CoV-2 para prevenir o desenvolvimento de doença e morte por COVID-19 em Córdoba, Argentina, no período de janeiro a junho de 2021. Métodos. Foi realizado um estudo de coorte retrospectivo em 1.139.458 residentes da província de Córdoba. Foram construídos modelos de regressão logística múltipla que relacionaram a vacinação à presença de SARS-CoV-2 ou morte por COVID-19, considerando comorbidades e fatores de risco para doenças crônicas e ajustando por sexo e idade. Resultados. Ter recebido uma ou duas doses da vacina na população geral reduziu o risco de adoecimento em 98,8% e 99,3%, respectivamente; e de morrer, em 83% e 96,5%, respectivamente. Naqueles que contraíram COVID-19, a probabilidade de morrer foi reduzida em 57% e 80%, respectivamente. Em relação à probabilidade de morte, o risco aumentou com o aumento da idade e para o sexo masculino, ou com a presença de obesidade, hipertensão arterial ou diabetes mellitus. Conclusão. A vacinação é efetiva e protege contra a possibilidade de contrair COVID-19, desenvolver doença grave ou morrer. A presença de obesidade, hipertensão arterial ou diabetes mellitus, em ordem decrescente, aumenta o risco de morte.

7.
Cad. Saúde Pública (Online) ; 38(4): ES219821, 2022. tab, graf
Article in Spanish | LILACS | ID: biblio-1374816

ABSTRACT

Los estudios seroepidemiológicos permiten conocer la distribución indirecta de las enfermedades, detectando marcadores séricos de inmunidad y demostrando infecciones no diagnosticadas en la población general. El objetivo fue estimar la seroprevalencia de anticuerpos contra el SARS-CoV-2, en Córdoba, Argentina, entre diciembre de 2020 y enero de 2021, e identificar factores asociados a la contagiosidad del virus. Se realizó un estudio observacional transversal, de base poblacional, con 3.225 individuos mayores de 2 años, residentes en Córdoba Capital, que fueron seleccionados mediante un diseño de muestreo aleatorio en múltiples etapas, proporcional a la distribución por género, franja etaria y nivel socioeconómico de la población de Córdoba. Las características clínicas, antropometría y comorbilidades se recogieron mediante entrevistas. Se realizó un test serológico cualitativo para la detección de anticuerpos IgG antinucleocápside para SARS-CoV-2 (ARCHITECT, Abbott). La seroprevalencia del SARS-CoV-2 se estimó en la población y por franja de edad, sexo, nivel socioeconómico y presencia de las patologías estudiadas. Las razones de prevalencia (RP) se estimaron usando un modelo de regresión log-binomial. La seropositividad para SARS-CoV-2 fue de 16,68% (IC95%: 15,41-18,01). Tener entre 2 y 18 años, residir en barrios con nivel socioeconómico bajo y la presencia de obesidad, aumentaron la oportunidad de seropositividad (RP = 1,50; IC95%: 1,10-2,04, RP = 1,91; IC95%: 1,34-2,67 y RP = 1,39; IC95%: 1,04-1,85). Los resultados indican que en Córdoba Capital existen atributos diferenciales que aumentan la posibilidad de ser seropositivo para SARS-CoV-2. Esto permite dirigir estrategias de vigilancia epidemiológica para reducir la propagación del virus.


Seroepidemiological studies help identify the indirect distribution of diseases, detecting serological markers of immunity and demonstrating undiagnosed infections in the general population. The objectives were to estimate the seroprevalence of SARS-CoV-2 antibodies in Córdoba, Argentina, from December 2020 to January 2021 and to identify factors associated with the virus' contagiousness. A population-based cross-sectional observational study was performed in 3,225 individuals over two years of age living in Córdoba city, selected by multiple-stage random sampling proportional to distribution by gender, age group, and socioeconomic status in the city's population. Clinical characteristics, anthropometry, and comorbidities were collected by interview. Qualitative serological testing was performed for detection of SARS-CoV-2 nucleocapsid IgG antibodies (ARCHITECT, Abbott). SARS-CoV-2 seroprevalence was estimated for the total population and by age group, sex, socioeconomic status, and presence of target diseases. Prevalence ratios (PR) were estimated using a log-binomial regression model. SARS-CoV-2 seropositivity was 16.68% (95%CI: 15.41-18.01). Age 2 to 18 years, living in neighborhoods with low socioeconomic status, and obesity increased the odds of seropositivity (PR = 1.50; 95%CI: 1.10-2.04, PR = 1.91; 95%CI: 1.34-2.67 and PR = 1.39; 95%CI: 1.04-1.85). The results indicate that the city of Córdoba displays differential attributes that increase the likelihood of a positive SARS-CoV-2 antibody test. This allows targeting epidemiological surveillance strategies to reduce the spread of the virus.


Os estudos soroepidemiológicos permitem conhecer a distribuição indireta das doenças, detectando marcadores séricos de imunidade e demonstrando infecções não diagnosticadas na população geral. O objetivo foi estimar a soroprevalência de anticorpos contra o SARS-CoV-2, em Córdoba, Argentina, entre dezembro de 2020 e janeiro de 2021, e identificar fatores associados à contagiosidade do vírus. Um estudo observacional transversal foi realizado, de base populacional, com 3.225 indivíduos maiores de 2 anos, residentes em Córdoba Capital, que foram selecionados por meio de um delineamento de amostragem aleatória em múltiplos estágios, proporcional à distribuição de gênero, a faixa etária e o nível socioeconômico da população de Córdoba. As características clínicas, antropometria e comorbidades foram coletadas por meio de entrevistas. Um teste sorológico qualitativo foi realizado para a detecção de anticorpos IgG anti-nucleocapsídeo para SARS-CoV-2 (ARCHITECT, Abbott). A soroprevalência do SARS-CoV-2 foi estimada na população e por faixa etária, sexo, nível socioeconômico e presença das patologias estudadas. Razões de prevalência (RP) foram estimadas usando um modelo de regressão log-binomial. A soropositividade para SARS-CoV-2 foi de 16,68% (IC95%: 15,41-18,01). Ter entre 2 e 18 años, residir em bairros com nível socioeconômico baixo e a presença de obesidade aumentaram a chance de soropositividade (RP = 1,50; IC95%: 1,10-2,04, RP = 1,91; IC95%: 1,34-2,67 e RP = 1,39; IC95%: 1,04-1,85). Os resultados indicam que em Córdoba Capital existem atributos diferenciais que aumentam a possibilidade de ser soropositivo para SARS-CoV-2. Isso permite direcionar estratégias de vigilância epidemiológica para reduzir a propagação do vírus.


Subject(s)
Humans , Child, Preschool , Child , Adolescent , COVID-19/epidemiology , Argentina/epidemiology , Brazil , Immunoglobulin G , Seroepidemiologic Studies , Cross-Sectional Studies , SARS-CoV-2 , Antibodies, Viral
8.
Enferm. glob ; 18(55): 455-461, jul. 2019. tab, graf
Article in Spanish | IBECS | ID: ibc-186247

ABSTRACT

Introducción: la musicoterapia se entiende por el uso de la música o sus elementos con fines terapéuticos. Su empleo en la enfermería es escaso más allá del uso de la intervención NIC 4400. Objetivo: conocer y analizar el grado de aceptación por parte de los estudiantes de enfermería ante la posible inclusión de la musicoterapia como asignatura en los programas educativos de los estudios de Grado en Enfermería. Método: se ha realizado un estudio observacional descriptivo de corte transversal con una muestra n=346 participantes. Resultados: los resultados muestran que el 93,93% de los alumnos sí incluirían la musicoterapia como una asignatura Optativa en los estudios de Grado en Enfermería, haciendo uso de ella en su futuro profesional


Introduction: music therapy is understood by the use of music or its elements for therapeutic purposes. Its use in nursing is scarce beyond the use of the NIC 4400 intervention. Objective: the research aims to know and analyze the degree of acceptance by nursing students regarding the possible inclusion of music therapy as a subject in the educational programs of the Nursing Degree studies. Method: a cross-sectional, observational, descriptive study was carried out with a sample of n=346 participants. Conclusion: the results show that 93.93% of the students did include music therapy as an optional subject in Nursing Degree studies, making use of it in their professional future


Subject(s)
Humans , Education, Nursing/trends , Music Therapy/methods , Curriculum/trends , Students, Nursing/statistics & numerical data , Surveys and Questionnaires
9.
PLoS One ; 12(2): e0171000, 2017.
Article in English | MEDLINE | ID: mdl-28192446

ABSTRACT

The nearest known population of common dolphins (Delphinus sp.) to the Colombian Caribbean occurs in a fairly restricted range in eastern Venezuela. These dolphins have not been previously reported in the Colombian Caribbean, likely because of a lack of study of the local cetacean fauna. We collected cetacean observations in waters of the Guajira Department, northern Colombia (~11°N, 73°W) during two separate efforts: (a) a seismic vessel survey (December 2009-March 2010), and (b) three coastal surveys from small boats (May-July 2012, May 2013, and May 2014). Here we document ten sightings of common dolphins collected during these surveys, which extend the known range of the species by ~1000 km into the southwestern Caribbean. We also collected nine skin biopsies in 2013 and 2014. In order to determine the taxonomic identity of the specimens, we conducted genetic barcoding and phylogenetic analyses using two mitochondrial markers, the Control Region (mtDNA) and Cytochrome b (Cytb). Results indicate that these specimens are genetically closer to the short-beaked common dolphin (Delphinus delphis) even though morphologically they resemble a long-beaked form (Delphinus sp.). However, the specific taxonomic status of common dolphins in the Caribbean and in the Western Atlantic remains unresolved. It is also unclear whether the distribution of the species between northern Colombia and eastern Venezuela is continuous or disjoined, or whether they can be considered part of the same stock.


Subject(s)
Common Dolphins/genetics , Cytochromes b/genetics , DNA Barcoding, Taxonomic/methods , DNA, Mitochondrial/genetics , Phylogeny , Animals , Caribbean Region , Cetacea/classification , Cetacea/genetics , Colombia , Common Dolphins/classification , Common Dolphins/physiology , DNA, Mitochondrial/chemistry , Geography , Polymerase Chain Reaction , Population Dynamics , Sequence Analysis, DNA/methods , Species Specificity , Venezuela
10.
Index enferm ; 21(4): 185-189, oct.-dic. 2012.
Article in Spanish | IBECS | ID: ibc-112106

ABSTRACT

Objetivo: Conocer la opinión de los pacientes acerca de los aspectos de la atención que reciben durante la hospitalización, que son importantes para lograr su bienestar. Metodología: Estudio cualitativo exploratorio. Los participantes fueron 30 informantes claves que estuvieron hospitalizados en cirugía general y fueron entrevistados en sus domicilios, posterior a su egreso, mediante una guía de entrevista semi-estructurada. Resultados: La atención técnica e interpersonal son esenciales para lograr el bienestar durante la hospitalización. Además es relevante la infraestructura, servicios otorgados por otros departamentos y cumplimiento de expectativas de los pacientes. Conclusión: Los pacientes hospitalizados perciben bienestar cuando reciben buen trato y son atendidos por personal competente. Es relevante la consideración de los otros aspectos que modulan la percepción del bienestar y dependen directamente del entorno hospitalario (AU)


Objective: The objective was to know the patient's opinion regarding the elements of the care they receive during hospitalization that are important to attain their well-being. Methodology: Exploratory qualitative study. The participants included 30 key informants who had been hospitalized in general surgery and were interviewed in their homes after they were discharged, using a semi-structured interview guide. Results: Technical and interpersonal care are essential factors to attain well-being during hospitalization. The infrastructures, services provided by other departments and meeting the patient's expectations are also important elements. Conclusion: Hospitalized patients perceive wellness when they are treated properly and attended by trained personnel. It is important to consider the other issues that modulate the perception on well-being, which depend directly on the hospital environment (AU)


Subject(s)
Humans , Patient Satisfaction , Hospitalization/statistics & numerical data , Quality of Health Care/statistics & numerical data , Patient-Centered Care/organization & administration
SELECTION OF CITATIONS
SEARCH DETAIL
...